RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy
As already posted and in advance of today's presentation ..ONCY's pelareorep is demonstrating leadership in the emerging field of oncolytic virus based cancer immunotherapy
Previous data from the AWARE-1 study demonstrated that addition of atezolizumab (atezo) to pela increased the CelTIL score (study’s primary endpoint) by more than 30% in 60% of HR+/HER2- early breast cancer (BC) patients. CelTIL is a composite measure of tumor cellularity and tumor-infiltrating lymphocytes (TILs) and has been associated with a better prognosis in BC. The increase in CelTIL score observed in AWARE-1 was accompanied by PD-L1 upregulation.
https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-congress/the-oncolytic-virus-pelareorep-primes-the-tumor-microenvironment-for-checkpoint-blockade-therapy-in-early-breast-cancer-patients-results-from-awar